Vericel Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vericel stock.
View analyst ratings for Vericel or view top-rated stocks.

Wall Street analysts have given Vericel a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vericel wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Vericel saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,890,000 shares, an increase of 62.5% from the March 15th total of 3,010,000 shares. Based on an average daily trading volume, of 942,600 shares, the short-interest ratio is presently 5.2 days.
View Vericel's Short Interest.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Vericel.

Vericel Co. (NASDAQ:VCEL) released its quarterly earnings results on Tuesday, February, 23rd. The biotechnology company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.05. The biotechnology company earned $45.23 million during the quarter, compared to analysts' expectations of $45.05 million. Vericel had a net margin of 0.12% and a trailing twelve-month return on equity of 0.13%.
View Vericel's earnings history.

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VCEL shares have increased by 385.3% and is now trading at $58.62.
View which stocks have been most impacted by COVID-19.

Vericel issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $161-164 million, compared to the consensus revenue estimate of $157.03 million.

8 equities research analysts have issued 1 year target prices for Vericel's shares. Their forecasts range from $31.00 to $60.00. On average, they anticipate Vericel's share price to reach $49.00 in the next twelve months. This suggests that the stock has a possible downside of 16.4%.
View analysts' price targets for Vericel or view top-rated stocks among Wall Street analysts.

6 employees have rated Vericel CEO Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among Vericel's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Vericel include Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Kodiak Sciences (KOD), Adaptive Biotechnologies (ADPT), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA) and Ablynx (ABLYF).
View all of VCEL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Momo (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by many different retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.92%), Calamos Advisors LLC (0.35%), State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.05%), Mesirow Financial Investment Management Inc. (0.03%) and Crossmark Global Holdings Inc. (0.02%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Jonathan Mark Hopper, Michael Halpin, Robert L Md Zerbe and Steven C Gilman.
View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Mesirow Financial Investment Management Inc., and Pacer Advisors Inc.. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Jonathan Mark Hopper, Michael Halpin, and Robert L Md Zerbe.
View insider buying and selling activity for Vericel or view top insider-selling stocks.

VCEL stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Scout Investments Inc., Louisiana State Employees Retirement System, Crossmark Global Holdings Inc., and Everence Capital Management Inc..
View insider buying and selling activity for Vericel or or view top insider-buying stocks.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCEL stock can currently be purchased for approximately $58.62.

Vericel has a market capitalization of $2.70 billion and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis.

Vericel employs 273 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel is headquartered at 64 SIDNEY STREET, CAMBRIDGE MA, 02139.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]